These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31114280)

  • 41. The influence of
    Ebid AIM; Ehab M; Ismail A; Soror S; Mahmoud MA
    J Drug Assess; 2019; 8(1):115-121. PubMed ID: 31231590
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparative Efficacy of Metformin and Glimepiride in Modulating Pharmacological Network to Increase BDNF Levels and Benefit Type 2 Diabetes-Related Cognitive Impairment.
    Anirudhan A; Ahmad SF; Emran TB; Angulo-Bejarano PI; Sharma A; Ahmed SSSJ
    Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Observational, Multicenter, Retrospective, Study on the Usage Patterns of the Fixed Dose Combination of Glimepiride, Metformin, and Voglibose in Type 2 Diabetes Management.
    Shamanna P; Jha PK; Makwana A; Shukla H; Bavishi C
    Cureus; 2024 Jan; 16(1):e52064. PubMed ID: 38348001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of metformin in treatment of patients with chronic obstructive pulmonary disease: a systematic review.
    Zhu A; Teng Y; Ge D; Zhang X; Hu M; Yao X
    J Thorac Dis; 2019 Oct; 11(10):4371-4378. PubMed ID: 31737323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of Serum IGF-1R, VEGF, and ET Levels with Bone Mineral Density in Type 2 Diabetic Mellitus Patients Treated with Metformin Plus
    Chen X; Li X; Kang S; Duan W
    Evid Based Complement Alternat Med; 2022; 2022():7707875. PubMed ID: 35497918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correction to: Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.
    Komatsu H; Enomoto M; Shiraishi H; Morita Y; Hashimoto D; Nakayama S; Funakoshi S; Hirano S; Terada Y; Miyamura M; Fujimoto S
    Diabetol Int; 2020 Oct; 11(4):393. PubMed ID: 33090124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sustained hypoglycemia with therapeutic use of repaglinide.
    Hantson P; El Balkhi S; Haufroid V; Laterre PF
    Acta Diabetol; 2020 Jun; 57(6):751-753. PubMed ID: 31776763
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
    Rosenstock J; Kahn SE; Johansen OE; Zinman B; Espeland MA; Woerle HJ; Pfarr E; Keller A; Mattheus M; Baanstra D; Meinicke T; George JT; von Eynatten M; McGuire DK; Marx N;
    JAMA; 2019 Sep; 322(12):1155-1166. PubMed ID: 31536101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
    Yu HM; Kim SJ; Chun SW; Park KY; Lim DM; Lee JM; Hong JH; Park KS
    Diabetes Res Clin Pract; 2019 Sep; 155():107796. PubMed ID: 31326458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Age-specific urinary metabolite signatures and functions in patients with major depressive disorder.
    Chen JJ; Xie J; Li WW; Bai SJ; Wang W; Zheng P; Xie P
    Aging (Albany NY); 2019 Sep; 11(17):6626-6637. PubMed ID: 31493765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus.
    Zeng DK; Xiao Q; Li FQ; Tang YZ; Jia CL; Tang XW
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.
    Wang SL; Dong WB; Dong XL; Zhu WM; Wang FF; Han F; Yan X
    Oncotarget; 2017 Sep; 8(42):72700-72713. PubMed ID: 29069819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus.
    Xie J; Li N; Jiang X; Chai L; Chen JJ; Deng W
    Diabetes Metab Syndr Obes; 2019; 12():519-526. PubMed ID: 31114280
    [No Abstract]   [Full Text] [Related]  

  • 55. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
    Kumar S
    Indian J Endocrinol Metab; 2021; 25(4):326-331. PubMed ID: 35136740
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.